Yang Tiantian, Wu Caixian, Li Peicong, Zhong Yuetong, Wu Wanyin, Wang Sumei, Yang Xiaobing
The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, P.R. China.
State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, P.R. China.
Integr Cancer Ther. 2024 Jan-Dec;23:15347354241237234. doi: 10.1177/15347354241237234.
The purpose of this overview is to assess systematic reviews (SRs)/ meta-analyses (MAs) of Huachansu (HCS) combination chemotherapy for treating non-small cell lung cancer (NSCLC) and provide summarized evidence for clinical decision making.
From the creation of the database to JUNE 2023, 8 databases in English and Chinese were searched. SRs/MAs that met the inclusion and exclusion criteria were included. Two reviewers independently screened research, extracted data and assessed methodological quality, risk of bias, report quality and evidence quality by using relevant criteria from AMSTAR-2, ROBIS scale, PRISMA, and GRADE system.
The short-term effect, long-term effect, quality of life improvement, safety and pain relief effect in 8 included SRs/MAs were assessed in this overview according to quantitative synthesis. Results assessed by AMSTAR-2, PRISMA, and ROBIS were generally unsatisfactory, with the results of the AMSTAR-2 assessment showing that all of them were of low or critically low quality; the number of items in the included research that were fully reported (compliance was 100%) by the PRISMA checklist was only 50%, while there were 38.10% of the research reporting less than 60% completeness; the ROBIS assessment showed a small number of systems to be low risk of bias. In addition, 26 items were rated as moderate quality, while 50.94% of items were rated as low or critically low quality by GRADE.
HCS may be a promising adjuvant therapy for NSCLC. However, high-quality SRs/MAs and randomized control trials (RCTs) should be conducted to provide sufficient evidence so as to draw a definitive conclusion.
本综述旨在评估华蟾素（HCS）联合化疗治疗非小细胞肺癌（NSCLC）的系统评价（SRs）/ 荟萃分析（MAs），为临床决策提供汇总证据。
从数据库创建至2023年6月，检索了8个中英文数据库。纳入符合纳入和排除标准的SRs/MAs。两名评价者独立筛选研究、提取数据，并使用AMSTAR-2、ROBIS量表、PRISMA和GRADE系统的相关标准评估方法学质量、偏倚风险、报告质量和证据质量。
本综述根据定量合成评估了8项纳入的SRs/MAs中的短期疗效、长期疗效、生活质量改善、安全性和疼痛缓解效果。AMSTAR-2、PRISMA和ROBIS评估结果总体不尽人意，AMSTAR-2评估结果显示所有研究质量均为低质量或极低质量；PRISMA清单完全报告（依从率为100%）的纳入研究项目数量仅为50%，而有38.10%的研究报告完整性低于60%；ROBIS评估显示少数系统偏倚风险较低。此外，26项被评为中等质量，而50.94%的项目被GRADE评为低质量或极低质量。
HCS可能是NSCLC一种有前景的辅助治疗方法。然而，应开展高质量的SRs/MAs和随机对照试验（RCTs）以提供充分证据，从而得出明确结论。
